Download this measure in English. BACK FACT-LCS English Downloads Download PDF Download DOC

Download scoring documents for this measure. BACK FAIT-F Scoring Downloads Download DOC

Download this measure in English. BACK FACT-BP English Downloads Download PDF Download DOC

View all available languages for this measure. BACK FACT-An Languages Afrikaans Albanian Arabic Bengali Bosnian Bulgarian Catalan Cebuano Chinese - Simplified Chinese - Traditional Croatian Czech Danish Dutch English Estonian Finnish French Georgian German Greek Gujarati Hebrew Hindi Hungarian Italian Indonesian Japanese Kannada Korean Latvian Lithuanian Macedonian Malay Malayalam Marathi Mongolian Montenegrin Norwegian Odia Polish Portuguese Punjabi Romanian Russian Serbian Sesotho Slovak Slovene Spanish Swedish Tagalog Tamil Telugu Thai Turkish Ukrainian Urdu Vietnamese Xhosa Zulu

Download this measure in English. BACK FACT-GOG-NTX-4 English Downloads Download PDF Download DOC

Download this measure in English. BACK FACIT-Sp-Ex English Downloads Download PDF Download DOC

NFOSI-18 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Ovarian Cancer Symptom Index - 18 Item Version For patients with Ovarian cancer; a FACT/NCCN-Ovarian Symptom Index LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview NCCNFACT Ovarian Index-18 (NFOSI-18) is an ovarian cancer-specific symptom index comprised of symptoms rated as highest priority by both oncology clinical experts and women with advanced ovarian cancer. Fifty-one women with advanced ovarian cancer rated the importance of 30 symptoms associated with advanced ovarian cancer. Ten gynecologic oncologists then rated symptoms according to whether they were predominantly disease- or treatment-related. Patient priorities were then reconciled with previously published clinician priorities for symptom measurement in ovarian cancer. Lower NFOSI-18 scores indicate greater high-priority symptom burden. Preliminary reliability suggests good internal consistency (α=0.80). The NFOSI-18 and its subscales were significantly positively associated with quality of life validity criteria and scores on the NFOSI-18 differed significantly by performance status, with poor performance status associated with lower NFOSI-18 scores. MEASURE NAME: National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Ovarian Cancer Symptom Index - 18 Item Version (NFOSI-18) VERSION: 2 NUMBER OF ITEMS: 18 PATIENT POPULATION: Ovarian cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Disease-Related Symptoms – Physical, Disease-Related Symptoms – Emotional, Treatment Side Effects, Function/Well-Being TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores possible. RELATED MEASURES: FACT-O , FOSI , FACT-G DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the NFOSI-18 can be obtained by registering for permission. Users are not permitted to translate the NFOSI-18 without permission from FACIT.org. Permission from FACIT.org to translate the NFOSI-18 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535. doi: 10.108/CNV-120022366. Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. Jensen, S., Rosenbloom, S., Beaumont, J., Abernethy, A., Jacobsen, P., Syrjala, K., & Cella, D. A new index of priority symptoms in advanced ovarian cancer. Gynecologic Oncology 2011; 120(2): 214-219. doi: 10.1016/j.ygyno.2010.09.025. Rosenbloom, S., Yount, S., Yost, K., Hampton, D., Paul, D., Abernethy, A., Jacobsen, P., Syrjala, K., Von Roenn, J., & Cella, D. Development and validation of eleven symptom indices to evaluate response to chemotherapy for advanced cancer: Measurement compliance with regulatory demands. Farquhar, I., Summers, K., Sorkin, A. (Eds.). The Value of Innovation: Impacts on Health, Life Quality and Regulatory Research. Emerald Group Publishing Inc. 2007; 16: 53-66. doi: 10.1016/S0194-3960(08)16003-6. Shaunfield, s., Jensen, s., Fisher, A., Webster, K., Shahabi, S., Ganguli, A., & Cella, D. Further content validation of the 18-item NCCN/FACT Ovarian Symptom Index and its Disease Related Symptom-Physical (DRS-P) subscale for use in advanced ovarian cancer clinical trials. Health and Quality of Life Outcomes 2019; 17: 185. doi: 10.1186/s12955-019-1253-3. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-O Functional Assessment of Cancer Therapy – Ovarian LEARN MORE FOSI Functional Assessment of Cancer Therapy Ovarian Cancer Symptom Index - 8 Item Version LEARN MORE FACT-G Functional Assessment of Cancer Therapy – General LEARN MORE

Download scoring documents for this measure. BACK NFHNSI-22 Scoring Downloads Download DOC

Download this measure in English. BACK FHNSI English Downloads Download PDF Download DOC

Download scoring documents for this measure. BACK FACT-AntiA Scoring Downloads Download DOC

View all available languages for this measure. BACK NFBlSI-18 Languages Afrikaans Arabic Bengali Bulgarian Chinese - Simplified Chinese - Traditional Croatian Czech Danish Dutch English Estonian Finnish French German Greek Gujarati Hebrew Hindi Hungarian Italian Japanese Kannada Korean Latvian Lithuanian Malayalam Marathi Norwegian Polish Portuguese Punjabi Romanian Russian Serbian Sesotho Slovak Slovene Spanish Swedish Tamil Telugu Thai Turkish Xhosa Zulu

View all available languages for this measure. BACK FACIT-SWiP Languages Dutch English Japanese Spanish